Literature DB >> 16831121

Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction?

Domenico D'Amico1, Franca Moschiano, Gennaro Bussone.   

Abstract

Treating migraine attacks early with triptans may be more effective than late triptan administration. However, in published studies, the definition of 'early' varied (in terms of time, pain intensity or presence of allodynia) or was unclear. Therefore, clear clinical indications have not been established. Appropriately designed trials to address this issue remain a priority. Early triptan treatment may also have disadvantages, including inadvertent treatment of tension-type headaches and danger of medication overuse. At present, only those migraineurs with rapid pain worsening, high pain recurrence rate and clinical indications of allodynia should be encouraged to take triptans as quickly as possible. This recommendation implies a requirement for patient education and the need to carefully tailor treatment to individual needs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16831121     DOI: 10.1586/14737175.6.7.1087

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  8 in total

1.  Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group study.

Authors:  Gianni Allais; Gennaro Bussone; Vincenzo Tullo; Pietro Cortelli; Fabio Valguarnera; Piero Barbanti; Giuliano Sette; Fabio Frediani; Giacomo D'Arrigo; Florindo d'Onofrio; Giancarlo Comi; Marcella Curone; Bruno Colombo; Stefano Omboni; Chiara Benedetto
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

2.  Triptan education and improving knowledge for optimal migraine treatment: an observational study.

Authors:  Eric P Baron; Shira Y Markowitz; Alyssa Lettich; Eric Hastriter; Brigitte Lovell; Kavita Kalidas; David William Dodick; Todd J Schwedt
Journal:  Headache       Date:  2014-02-12       Impact factor: 5.887

Review 3.  Favorable outcome of early treatment of new onset child and adolescent migraine-implications for disease modification.

Authors:  James A Charles; B L Peterlin; Alan M Rapoport; Steven L Linder; Marielle A Kabbouche; Fred D Sheftell
Journal:  J Headache Pain       Date:  2009-06-09       Impact factor: 7.277

4.  Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.

Authors:  Anna Ferrari; Diego Pinetti; Alfio Bertolini; Ciro Coccia; Emilio Sternieri
Journal:  Eur J Clin Pharmacol       Date:  2008-01-08       Impact factor: 2.953

5.  Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial.

Authors:  Piero Barbanti; Luisa Fofi; Valentina Dall'Armi; Cinzia Aurilia; Gabriella Egeo; Nicola Vanacore; Stefano Bonassi
Journal:  J Headache Pain       Date:  2012-03-30       Impact factor: 7.277

6.  Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.

Authors:  Gianni Allais; Vincenzo Tullo; Pietro Cortelli; Piero Barbanti; Fabio Valguarnera; Giuliano Sette; Florindo D'Onofrio; Marcella Curone; Dario Zava; Deborha Pezzola; Giorgio Reggiardo; Stefano Omboni; Fabio Frediani; Gennaro Bussone; Chiara Benedetto
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

7.  Results from a pharmacy-based patient survey on the use of a fixed combination analgesic containing acetylsalicylic acid, paracetamol and caffeine by self-diagnosing and self-treating patients.

Authors:  Charly Gaul; Heidemarie Gräter; Thomas Weiser
Journal:  Springerplus       Date:  2016-06-14

Review 8.  Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine.

Authors:  Gianni Allais; Chiara Benedetto
Journal:  Drug Des Devel Ther       Date:  2016-10-03       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.